Skip to Content
Merck
  • Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy.

Exploiting loss of heterozygosity for allele-selective colorectal cancer chemotherapy.

Nature communications (2020-03-13)
Veronica Rendo, Ivaylo Stoimenov, André Mateus, Elin Sjöberg, Richard Svensson, Anna-Lena Gustavsson, Lars Johansson, Adrian Ng, Casey OʼBrien, Marios Giannakis, Per Artursson, Peter Nygren, Ian Cheong, Tobias Sjöblom
ABSTRACT

Cancer chemotherapy targeting frequent loss of heterozygosity events is an attractive concept, since tumor cells may lack enzymatic activities present in normal constitutional cells. To find exploitable targets, we map prevalent genetic polymorphisms to protein structures and identify 45 nsSNVs (non-synonymous small nucleotide variations) near the catalytic sites of 17 enzymes frequently lost in cancer. For proof of concept, we select the gastrointestinal drug metabolic enzyme NAT2 at 8p22, which is frequently lost in colorectal cancers and has a common variant with 10-fold reduced activity. Small molecule screening results in a cytotoxic kinase inhibitor that impairs growth of cells with slow NAT2 and decreases the growth of tumors with slow NAT2 by half as compared to those with wild-type NAT2. Most of the patient-derived CRC cells expressing slow NAT2 also show sensitivity to 6-(4-aminophenyl)-N-(3,4,5-trimethoxyphenyl)pyrazin-2-amine (APA) treatment. These findings indicate that the therapeutic index of anti-cancer drugs can be altered by bystander mutations affecting drug metabolic genes.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
N-Acetyl-D-penicillamine, for HPLC derivatization, ≥99.0% (T)
Sigma-Aldrich
Anti-phospho-Histone H3 (Ser10) Antibody, clone MC463, rabbit monoclonal, culture supernatant, clone MC463, Upstate®
Sigma-Aldrich
Anti-α-Tubulin antibody, Mouse monoclonal, clone AA13, purified from hybridoma cell culture
Sigma-Aldrich
Monoclonal Anti-α-Tubulin antibody produced in mouse, clone DM1A, ascites fluid
Sigma-Aldrich
Aurora Kinase A active human, recombinant, expressed in baculovirus infected Sf9 cells, ≥90% (SDS-PAGE)